progerinin
Peptideexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Aug 24, 2020 (NCT04512963)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Prelamin-A/CINHIBITOR
LMNA inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC1(C)Oc2cc3oc(=O)ccc3cc2C[C@@H]1OC/C=C/c1ccccc1- Mol. weight
- 362.43 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1631723 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06775041 | Phase 2 | Jan 31, 2025 | — |
| NCT05847179 | Phase 2 | Jan 1, 2025 | — |
| NCT04512963 | Phase 1 | Aug 24, 2020 | Amarex Clinical Research, PRG Science & Technology Co., Ltd. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Amarex Clinical Research | For profit | 1 | 0 | 1 | 2020 |
| PRG Science & Technology Co., Ltd. | For profit | 1 | 1 | 1 | 2020 |
2 organizations
Page 1 / 1